Zheng, Hanrui <br/><br/>
Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.  [electronic resource] 

 -  Journal of medical economics  Apr 2020 
 - 347-352 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2019.1707211  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--economics<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cost-Benefit Analysis<br/>Disease-Free Survival<br/>Humans<br/>Liver Neoplasms<br/>Markov Chains<br/>Sorafenib--therapeutic use<br/>Treatment Outcome<br/>United States<br/>alpha-Fetoproteins--administration & dosage<br/>Ramucirumab